Medigene sells U.S. rights for Veregen

Cancer immunotherapy company Medigene AG (Xetra:MDG1) granted the Sandoz Inc. unit of Novartis AG (NYSE:NVS; SIX:NOVN) U.S. rights to Veregen sinecatechins (SB03). Financial terms were not disclosed.

Medigene will exclusively supply Veregen to Sandoz's dermatology business, Fougera Pharmaceuticals Inc., which will reimburse Medigene for supply costs...